Keith Burkhart

Keith Burkhart

Auto-generated profile, based on publicly available information

Keith Burkhart

United States Food and Drug Administration, Silver Spring, MD, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Clinical Toxicology
Verified
Journal Article
Closed access
RFRita Farah
Rita Farah
ZKZiad Kazzi
Ziad Kazzi
JBJeffrey Brent
Jeffrey Brent
KBKeith Burkhart
Keith Burkhart
PWPaul Wax
Paul Wax
OGOn behalf of the Toxicology Investigators Consortium FACT Study Group
On behalf of the Toxicology Investigators Consortium FACT Study Group
In August 2021, the Centers for Disease Control and Prevention (CDC) released a health alert following the rapid increase in ivermectin prescriptions and reports of severe illness associated with u...

21 February 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
VGVictoria Gershuny
Victoria Gershuny
JFJeffry Florian
Jeffry Florian
RSRutger van der Schrier
Rutger van der Schrier
MDMichael C. Davis
Michael C. Davis
PSPablo Salcedo
Pablo Salcedo
DSDavid G. Strauss
David G. Strauss
Benzodiazepines can exacerbate opioid-induced respiratory depression by furthering the decrease in central respiratory drive and causing loss of upper airway patency potentially leading to airway obstruction. This study aimed to determine if co-administration of benzodiazepines and opioids significantly decreases hypercapnic ventilation compared with opioids alone. We conducted a randomised, double-blind, four-period crossover trial in 20 healthy participants to assess whether i.v. midazolam (0.0375 mg kg-1 in the first five participants; 0.075 mg kg-1 in 15 participants) plus oral oxycodone (10 mg), compared with oxycodone alone, decreases minute ventilation at an end-tidal carbon dioxide (Pco2) of 7.3 kPa using modified Read rebreathing methodology. Midazolam administered with oxycodone, compared with oxycodone alone, did not significantly decrease minute ventilation at an end-tidal Pco2 of 7.3 kPa (23.5 vs 25.2 L min-1; mean difference -1.7 L min-1, one-sided 95% confidence interval -∞ to 1.6; P=0.21). However, midazolam plus oxycodone increased resting end-tidal Pco2 compared with oxycodone alone (5.8 vs 5.6 kPa; mean difference 0.2 kPa, 95% confidence interval 0.0-0.4). Nine of 15 (60%) participants fell asleep or snored on midazolam plus oxycodone, compared with 0 of 15 (0%) on oxycodone alone. Midazolam co-administered with oxycodone did not decrease hypercapnic ventilation, compared with oxycodone alone, but did affect tidal volume, ventilatory frequency, and resting end-tidal Pco2. These findings support the hypothesis that benzodiazepines influence ventilation by inducing relaxation of the respiratory muscles and highlight the need for additional investigations to elucidate the potential for upper airway obstruction when benzodiazepines and opioids are co-administered. NCT04310579.


2 December 2023 in Clinical Toxicology
Verified
Journal Article
Closed access
KKKaren Konkel
Karen Konkel
KBKeith Burkhart
Keith Burkhart
CCCarmen Cheng
Carmen Cheng
RLRegina Lee
Regina Lee
TMTheresa Michele
Theresa Michele
LMLynda Mcculley
Lynda Mcculley

15 August 2023 in Journal of Medical Toxicology
Verified
Journal Article
Closed access
PDF file
MSMark Simon
Mark Simon
JBJennie Buchanan
Jennie Buchanan
JSJonathan Schimmel
Jonathan Schimmel
JBJeffrey Brent
Jeffrey Brent
KBKeith Burkhart
Keith Burkhart
OGOn behalf of the Toxicology Investigators Consortium FACT Study Group
On behalf of the Toxicology Investigators Consortium FACT Study Group

10 January 2024 in Drugs
Verified
Journal Article
Closed access
PDF file
JSJonathan Schimmel
Jonathan Schimmel
LELindsey Claire Epperson
Lindsey Claire Epperson
KAKim Aldy
Kim Aldy
PWPaul Wax
Paul Wax
JBJeffrey Brent
Jeffrey Brent
TGthe Toxicology Investigators Consortium FACT Study Group
the Toxicology Investigators Consortium FACT Study Group